Skip to main content

Table 4 Comparative analysis of AITL patients who received prior auto-HCT vs no prior auto-HCT

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Outcomes No prior auto-HCT (N = 151) Prior auto-HCT (N = 98) p value
N Prob (95% CI) N Prob (95% CI)
NRM 151   98   0.25
1-year   17 (11–23)%   22 (14–30)% 0.33
2-year   21 (15–28)%   31 (22–41)% 0.08
3-year   22 (16–29)%   33 (23–43)% 0.07
4-year   26 (19–34)%   36 (26–47)% 0.11
Progression/relapse 151   98   0.69
1-year   16 (11–22)%   15 (8–22)% 0.77
2-year   22 (15–29)%   16 (9–24)% 0.23
3-year   23 (16–30)%   17 (10–25)% 0.28
4-year   24 (17–31)%   17 (10–25)% 0.21
PFS 151   98   0.45
1-year   68 (60–75)%   64 (54–73)% 0.56
2-year   57 (49–65)%   53 (43–63)% 0.53
3-year   55 (47–64)%   50 (40–61)% 0.43
4-year   50 (42–59)%   47 (36–57)% 0.60
Overall survival 151   98   0.81
1-year   73 (65–80)%   74 (65–82)% 0.81
2-year   65 (57–72)%   59 (49–69)% 0.43
3-year   61 (53–69)%   58 (47–68)% 0.63
4-year   57 (49–65)%   54 (44–65)% 0.70
  1. Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, HCT hematopoietic cell transplantation